Covidien plc (COV) Plans Quarterly Dividend of $0.26
Covidien plc (NYSE:COV) declared a quarterly dividend on Thursday, March 21st. Shareholders of record on Thursday, April 4th will be given a dividend of $0.26 per share on Friday, May 3rd. This represents a $1.04 dividend on an annualized basis and a yield of 1.59%.
COV has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Covidien plc from $66.00 to $69.00 in a research note to investors on Wednesday. They now have a “sector perform” rating on the stock. On the ratings front, analysts at Atlantic Securities initiated coverage on shares of Covidien plc in a research note to investors on Wednesday, March 6th. They set an “overweight” rating and a $75.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Covidien plc in a research note to investors on Tuesday, March 5th.
Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Covidien plc presently has a consensus rating of “Buy” and a consensus price target of $67.80.
Covidien plc (NYSE: COV) opened at 65.50 on Thursday. Covidien plc has a 1-year low of $50.25 and a 1-year high of $66.20. The stock’s 50-day moving average is currently $63.6. The company has a market cap of $30.919 billion and a price-to-earnings ratio of 16.65.
Covidien plc (NYSE: COV) last released its earnings data on Friday, January 25th. The company reported $1.10 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.06 by $0.04. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $3.00 billion. During the same quarter in the prior year, the company posted $1.13 earnings per share. The company’s quarterly revenue was up 5.5% on a year-over-year basis. On average, analysts predict that Covidien plc will post $4.49 earnings per share for the current fiscal year.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.